RPG Life Sciences Limited has informed the Exchange regarding 'Machine readable and searchable form of Financial Results for the quarter and year ended March 31, 2026 '.
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
RPG Life Sciences reported FY2026 standalone revenue of Rs. 70,752 lakhs, up 8.3% from Rs. 65,343 lakhs in FY2025. Profit after tax stood at Rs. 11,735 lakhs, marginally higher than Rs. 11,517 lakhs, with EPS of Rs. 110.80 versus Rs. 69.64 in the prior year. The board recommended a dividend of Rs. 24 per equity share (300% on Rs. 8 face value), subject to shareholder approval. Dr. Pratit Samdani was appointed as Additional Non-Executive Independent Director for 5 years. Notable exceptional items include Rs. 2,475 lakhs net insurance claim income from a fire incident and Rs. 1,169 lakhs impact from new labour codes. The company also plans to transfer its API division to wholly-owned subsidiary RPG Active Pharma Limited.
Revenue growth of 8.3% shows steady business momentum, though flat PAT reflects headwinds from labour code changes and asset impairment. The healthy dividend payout signals management confidence. The API spin-off to a subsidiary could unlock value and streamline operations.